Besides, the tribunal has restrained the Competition Commission of India (CCI) from imposing penalty on the officials of these companies, who have been held responsible for contravention of Competition Act.
The tribunal's order comes more than a year after the CCI had slapped Rs 64 crore fine on the two firms for alleged collusive bidding in supply of a meningitis vaccine to the government for Haj pilgrims.
The matter relates to supply of polysaccharide Quadrivalent Meningococcal Meningitis (QMMV).
The prices quoted by GSK and Sanofi were also different, the tribunal noted.
Also Read
"Even if we were to assume that the Commission had taken a deliberate decision to impose penalty at three per cent of the turnover of the appellants based on the financial statements filed by them, the same is legally unsustainable because the Commission has taken into consideration the entire turnover of the appellants of which QMMV is a miniscule fraction," the tribunal said.
In June 2016, the watchdog had imposed a fine of Rs 60.45 crore on GlaxoSmithKline (GSK) and Rs 3.04 crore on Sanofi as well as directed them to cease and desist" from anti- competitive practices.
The quantum of penalties amounted to the respective 3 per cent of their three-year average turnover. The turnover figures for the financial years 2008, 2009 and 2010 were taken into account.
Disclaimer: No Business Standard Journalist was involved in creation of this content